Cantor Fitzgerald analyst Louise Chen maintained a Hold rating on Endo International (NASDAQ: ENDP) today and set a price target of $18. The company’s shares opened today at $17.54, close to its 52-week high of $18.50.
Chen observed:
“. After speaking with four physicians that treat up to ~50 patients per month for cellulite, we are raising our 12-month PT for ENDP shares to $18 from $12 because we are increasingly positive on the market opportunity for this product, if approved. Despite the increase in our PT, we are still maintaining our Neutral rating because we think the risk reward for ENDP’s existing business and new opportunities is already accurately reflected in its stock price. Better-than-expected Phase 3 data for CCH, a pick up in ENDP’s generics business and/or lower-than- expected calls on ENDP’s cash (debt, testosterone) would make us more positive on the stock.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 13.3% and a 43.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Endo International with a $17.68 average price target, representing a 0.8% upside. In a report issued on October 12, Mizuho Securities also reiterated a Hold rating on the stock with a $18 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.50 and a one-year low of $5.27. Currently, Endo International has an average volume of 4.55M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals.
